Posted on June 6, 2020 by Sitemaster
Last month, we looked at Level 1 evidence (highest level, superseding all previous studies) that for unfavorable-risk patients, brachy boost therapy (BBT) — i.e., external beam therapy (EBRT) with a brachytherapy boost to the prostate — has better results when accompanied by 18 months of androgen deprivation therapy (ADT) (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, brachy boost, high, intermediate, radiation, risk, therapy | 2 Comments »
Posted on October 26, 2018 by Sitemaster
Stereotactic body radiation therapy or SBRT (sometimes referred to as SABR or SHARP or CyberKnife) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: body, intermediate, low, radiation, risk, SBRT, sterotactic | 10 Comments »
Posted on October 16, 2018 by Sitemaster
A clinical research team from the Mayo Clinic (Routman et al.) has reported 10-year oncological results on 974 consecutive low- and intermediate-risk patients treated with low-dose-rate brachytherapy monotherapy (using iodine-125 seeds) from 1998 to 2013. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachytherapy, intermediate, low, low-dose-rate, monotherapy, outcome, risk, seeds | 3 Comments »
Posted on July 5, 2018 by Sitemaster
A new paper from the Emberton-Ahmed group in the UK has reported 5-year follow-up data from a cohort of > 600 patients with clinically significant, localized prostate cancer, all treated with focal forms of high-intensity focused ultrasound (HIFU). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: focal, HIFU, high, high-intensity, intermediate, risk, ultrasound | 7 Comments »
Posted on March 20, 2018 by Sitemaster
Last week, we saw that escalated dose did not improve 10-year overall survival in high-risk men (see this link). The latest published findings of the randomized clinical trial (RTOG 0126) prove that 8-year overall survival was not improved in intermediate-risk men who received a higher radiation dose. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: intermediate, outcome, radiation, risk, survival, therapy | 3 Comments »
Posted on October 30, 2017 by Sitemaster
Two matters of concern to many prostate cancer patients who are considering radiation therapy as a treatment for their prostate cancer are : (a) Should I be having a short course of androgen deprivation therapy (ADT) along with the radiation therapy? (b) How well will I recover normal serum testosterone levels after such short-term treatment? … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, intermediate, neoadjuvant, radiation, risk | 3 Comments »
Posted on October 26, 2017 by Sitemaster
The first randomized clinical trial to prove that brachy boost radiotherapy had better oncological outcomes among high-risk patients was the one published by Sathya et al. in 2005. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: boost, brachy, high, intermediate, outcome, radiation, risk, survival | 6 Comments »
Posted on August 4, 2017 by Sitemaster
It is now clear that men who meet NCCN criteria for very low- and low-risk forms of prostate cancer are almost invariably good candidates for initial management on active surveillance (i.e., just monitoring as opposed to immediate treatment). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, favorab le, intermediate, low, outcome, risk, surveillance, unfavorable | 8 Comments »
Posted on March 16, 2017 by Sitemaster
Several randomized clinical trials have established the superior oncological outcomes of the combination of external beam radiotherapy with a high-dose-rate brachytherapy boost (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: boost, brachytherapy, high, intermediate, progression-free, risk, survival | 1 Comment »
Posted on March 21, 2016 by Sitemaster
A new review article in the journal Oncology provides us with an overview of the appropriate management of men with “favorable” and “unfavorable” forms of intermediate-risk prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: favorable, intermediate, Management, risk, unfavorable | Leave a comment »
Posted on January 9, 2016 by Sitemaster
The EORTC trial 22991 was designed and implemented to compare external beam radiation therapy (EBRT) + short-term androgen deprivation therapy (ADT) to EBRT alone as first-line therapy in patients with intermediate- and high-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ADT, androgen, deprivation, EBRT, external beam, high, intermediate, radiation, risk | 5 Comments »
Posted on December 3, 2015 by Sitemaster
According to a report this morning on the UroToday web site, Dr. Eric Small presented an update yesterday on so-called “intermediate atypical”, metastatic, castration-resistant prostate cancer (mCRPC) — at a general session of the 2015 meeting of the Society of Urologic Oncology in Washington, DC. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: atypical, castration-resistant, IAC, intermediate, mCRPC, metatstatic | 5 Comments »
Posted on November 6, 2015 by Sitemaster
From the perspective of the disinterested observer, one of the very least edifying aspects of issues related to the management of prostate cancer has been the nearly 50-year-long “discussion” between the urology community and the radiation oncology community about the most appropriate way(s) to treat localized disease. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "best", high, intermediate, localized, registry, risk, Treatment, trial | 11 Comments »
Posted on November 2, 2015 by Sitemaster
The ASCENDE-RT randomized clinical trial demonstrated that the combination of external beam radiation therapy with a brachytherapy boost (EBRT + BT) significantly reduced biochemical progression-free survival. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: boost, brachytherapy, BT, EBRT, external beam, high, intermediate, mortality, outcome, radiation, risk | 3 Comments »
Posted on May 31, 2015 by Sitemaster
A sophisticated presentation at the annual meeting of the American Society of Clinical Oncology today (on behalf of the West Coast Prostate Cancer “Dream Team”) gave us insights into the the development of neuroendocrine forms of drug-resistant prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: histology, intermediate, neuroendocrine, small cell | 1 Comment »
